ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
Income Statement
Follow revenue through to earnings.
Revenue
$81.36M
FY 2025 · Annual
+14.9% YoYOperating Income
-$108.38M
FY 2025 · Annual
Net Income
-$142.62M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.92M | 209.91M | 69.56M | 70.84M | 81.36M |
| Cost of Revenue | 1.39M | 3.3M | 2.53M | 5.95M | 7.67M |
| Gross Profit | 32.52M | 206.61M | 67.03M | 64.89M | 73.68M |
| Gross Margin | 95.9% | 98.4% | 96.4% | 91.6% | 90.6% |
| Research & Development | 158M | 186.46M | 127.13M | 109.63M | 104.01M |
| Selling, General & Admin | 136.24M | 143.49M | 105.89M | 85.91M | (6.82M) |
| Operating Expenses | 294.24M | 329.95M | 233.02M | 195.54M | 182.06M |
| Depreciation & Amortization | 2.63M | 2.39M | 3.27M | 3.28M | 1.88M |
| EBITDA | (230.54M) | (107.7M) | (145.83M) | (102.65M) | (89.27M) |
| EBITDA Margin | -679.7% | -51.3% | -209.6% | -144.9% | -109.7% |
| Operating Income | (261.72M) | (123.34M) | (165.99M) | (130.65M) | (108.38M) |
| Operating Margin | -771.6% | -58.8% | -238.6% | -184.4% | -133.2% |
| Interest Income | 66K | 2.57M | 10.54M | 12.27M | 8.81M |
| Interest Expense | 18.34M | 36.73M | 46.33M | 50.21M | 51.63M |
| Other Income / Expenses | 10.22M | (33.56M) | (34.96M) | (27.03M) | (34.4M) |
| Income Before Tax | (251.51M) | (156.9M) | (200.95M) | (157.68M) | (142.78M) |
| Pre-Tax Margin | -741.5% | -74.7% | -288.9% | -222.6% | -175.5% |
| Income Tax Expense | (21.48M) | 227K | 39.11M | 166K | (157K) |
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Net Margin | -678.2% | -74.9% | -345.1% | -222.8% | -175.3% |
| EPS (Basic) | (3.00) | (1.99) | (2.94) | (1.62) | (1.12) |
| EPS (Diluted) | (3.00) | (1.99) | (2.94) | (1.62) | (1.12) |
| 76.75M | 78.15M | 81.71M | 97.16M | 127.07M | |
| 76.75M | 78.15M | 81.71M | 97.16M | 127.07M |
ADCT Earnings Waterfall · TTM
NYSE:ADCT · Revenue to Net Income
Key Ratios
Analysis
$79.2M of revenue converted into -$137.0M of net income for the selected period. Gross margin is 90.9% and net margin is -184.0%, showing how much revenue survives after costs and taxes. EPS is $-1.05, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| S-3 | S-3 filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 4, 2026 |
How much revenue does ADCT generate?
ADC Therapeutics S.A. (ADCT) reported $81.36M of revenue in fiscal 2025.
Is ADCT profitable?
ADC Therapeutics S.A. (ADCT) reported -$142.62M of net income, with a net margin of -175.3%.
Continue the stock analysis
Jump to another research area for this company.